好中球減少症治療のアジア太平洋市場2020-2026:流通経路別(小売薬局、病院薬局、オンライン薬局)、治療別、地域別

◆英語タイトル:Asia Pacific Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Country, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20OCT165
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年6月30日
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:中国、日本、インド、韓国、シンガポール、マレーシア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD1,500 ⇒換算¥162,000見積依頼/購入/質問フォーム
Global License(法人利用)USD2,520 ⇒換算¥272,160見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、好中球減少症治療のアジア太平洋市場について、市場範囲・調査手法、市場概要、流通経路別(小売薬局、病院薬局、オンライン薬局)分析、治療別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・好中球減少症治療のアジア太平洋市場規模:流通経路別(小売薬局、病院薬局、オンライン薬局)
・好中球減少症治療のアジア太平洋市場規模:治療別
・好中球減少症治療のアジア太平洋市場規模:地域別
・企業概要
【レポートの概要】

The Asia Pacific Neutropenia Treatment Market would witness market growth of 7.6% CAGR during the forecast period (2020-2026).

Neutropenia itself has no specific symptoms but is usually treated with a fever or infection. Often, persistent infection is also what leads doctors to test blood cell counts to identify blood cell cancers such as leukemia. Severe infections can develop quickly when a patient is neutropenic and become overwhelming within minutes to hours. Fortunately, since doctors expect potential changes in immune responses during multiple cancer treatments, they pay careful attention to variations in blood counts to avoid these events.

Cytotoxic chemotherapy can cause severe and often prolonged neutropenia, which can lead to Retailization for fever care or possibly fatal infection. While deep sustained neutropenia is more likely to occur in the pre-engraft process of hematopoietic cell transplantation and in patients undergoing acute leukemia induction therapy, chemotherapy-related neutropenia that also occurs in patients undergoing standard-dose chemotherapy for certain neoplasms. To eliminate infectious risks, recombinant human granulocyte stimulating factor (G-CSF; filgrastim and pegylated filgrastim) and granulocyte-macrophage stimulating factor (GM-CSF; sargramostim) have been used to decrease the length and degree of neutropenia.

A rise in the prevalence of leukemia, an increase in R&D activities and the production of new drugs, and a paradigm change from branded drugs to biosimilars in cancer-friendly treatment, are transforming the global neutropenia treatment industry. Nevertheless, high costs for the diagnosis of neutropenia and stringent rules for the clearance of products hinder the growth of the market. On the contrary, the robust neutropenia drug pipeline will open up new opportunities for market players over the coming years.

Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.

Scope of the Study
Market Segmentation:

By Distribution Channel
• Retail pharmacies
• Hospital pharmacies and
• Online pharmacies

By Treatment
• Colony-stimulating factor
• Antibiotics
• Antifungals and
• Antivirals

By Country
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled
• Amgen, Inc.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceuticals Industries Ltd.
• BeyondSpring, Inc.
• Spectrum Pharmaceuticals, Inc.
• Kyowa Kirin Co., Ltd. (Kirin Company)
• Mylan N.V.
• Cellerant Therapeutics, Inc.
• Partner Therapeutics, Inc.

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Neutropenia Treatment Market, by Distribution Channel
1.4.2 Asia Pacific Neutropenia Treatment Market, by Treatment
1.4.3 Asia Pacific Neutropenia Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Neutropenia Treatment Market by Distribution channel
3.1 Asia Pacific Retail pharmacies Market by Country
3.2 Asia Pacific Hospital pharmacies Market by Country
3.3 Asia Pacific Online pharmacies Market by Country
Chapter 4. Asia Pacific Neutropenia Treatment Market by Treatment
4.1 Asia Pacific Colony-stimulating factor Market by Country
4.2 Asia Pacific Antibiotics Market by Country
4.3 Asia Pacific Antifungals Market by Country
4.4 Asia Pacific Antivirals Market by Country
Chapter 5. Asia Pacific Neutropenia Treatment Market by Country
5.1 China Neutropenia Treatment Market
5.1.1 China Neutropenia Treatment Market by Distribution channel
5.1.2 China Neutropenia Treatment Market by Treatment
5.2 Japan Neutropenia Treatment Market
5.2.1 Japan Neutropenia Treatment Market by Distribution channel
5.2.2 Japan Neutropenia Treatment Market by Treatment
5.3 India Neutropenia Treatment Market
5.3.1 India Neutropenia Treatment Market by Distribution channel
5.3.2 India Neutropenia Treatment Market by Treatment
5.4 South Korea Neutropenia Treatment Market
5.4.1 South Korea Neutropenia Treatment Market by Distribution channel
5.4.2 South Korea Neutropenia Treatment Market by Treatment
5.5 Singapore Neutropenia Treatment Market
5.5.1 Singapore Neutropenia Treatment Market by Distribution channel
5.5.2 Singapore Neutropenia Treatment Market by Treatment
5.6 Malaysia Neutropenia Treatment Market
5.6.1 Malaysia Neutropenia Treatment Market by Distribution channel
5.6.2 Malaysia Neutropenia Treatment Market by Treatment
5.7 Rest of Asia Pacific Neutropenia Treatment Market
5.7.1 Rest of Asia Pacific Neutropenia Treatment Market by Distribution channel
5.7.2 Rest of Asia Pacific Neutropenia Treatment Market by Treatment
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[好中球減少症治療のアジア太平洋市場2020-2026:流通経路別(小売薬局、病院薬局、オンライン薬局)、治療別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆